Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children
Authors:
- Shereen KatrakSKShereen Katrak
- Anne GasasiraAGAnne Gasasira
- Emmanuel ArinaitweEAEmmanuel Arinaitwe
- Abel KakuruAKAbel Kakuru
- Humphrey WanziraHWHumphrey Wanzira
- Victor BigiraVBVictor Bigira
- Taylor G SandisonTSTaylor G Sandison
- Jaco HomsyJHJaco Homsy
- Jordan W TapperoJTJordan W Tappero
- Moses R KamyaMKMoses R Kamya
- Grant DorseyGDGrant Dorsey
Open Access
- 30 November 2009
- journal article
- research article
- Published by Springer Nature in Malaria Journal
- Vol. 8 (1) , 272
Abstract
Background: Artemisinin combination therapy has become the standard of care for uncomplicated malaria in most of Africa. However, there is limited data on the safety and tolerability of these drugs, especially in young children and patients co-infected with HIV. Methods: A longitudinal, randomized controlled trial was conducted in a cohort of HIV-infected and uninfected children aged 4-22 months in Tororo, Uganda. Participants were randomized to treatment with artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DP) upon diagnosis of their first episode of uncomplicated malaria and received the same regimen for all subsequent episodes. Participants were actively monitored for adverse events for 28 days and then passively for up to 63 days after treatment. This study was registered in ClinicalTrials.gov (registration # NCT00527800). Results: A total of 122 children were randomized to AL and 124 to DP, resulting in 412 and 425 treatments, respectively. Most adverse events were rare, with only cough, diarrhoea, vomiting, and anaemia occurring in more than 1% of treatments. There were no differences in the risk of these events between treatment groups. Younger age was associated with an increased risk of diarrhoea in both the AL and DP treatment arms. Retreatment for malaria within 17-28 days was associated with an increased risk of vomiting in the DP treatment arm (HR = 6.47, 95% CI 2.31-18.1, p < 0.001). There was no increase in the risk of diarrhoea or vomiting for children who were HIV-infected or on concomitant therapy with antiretrovirals or trimethoprim-sulphamethoxazole prophylaxis. Conclusion: Both AL and DP were safe and well tolerated for the treatment of uncomplicated malaria in young HIV-infected and uninfected children. Trial Registration: ClinicalTrials.gov: NCT00527800; http://clinicaltrials.gov/ct2/show/NCT00527800Keywords
This publication has 23 references indexed in Scilit:
- Artemether‐Lumefantrine versus Dihydroartemisinin‐Piperaquine for Falciparum Malaria: A Longitudinal, Randomized Trial in Young Ugandan ChildrenClinical Infectious Diseases, 2009
- Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treating Uncomplicated Malaria: A Randomized Trial to Guide Policy in UgandaPLOS ONE, 2008
- A Major Transition in Malaria Treatment: The Adoption and Deployment of Artemisinin-Based Combination TherapiesThe American Journal of Tropical Medicine and Hygiene, 2007
- Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina FasoClinical Infectious Diseases, 2007
- Efficacy and safety of dihydroartemisinin-piperaquineTransactions of the Royal Society of Tropical Medicine and Hygiene, 2007
- Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized TrialPLoS Clinical Trials, 2007
- Malaria Pharmacovigilance in AfricaDrug Safety, 2007
- Safety and efficacy of dihydroartemisinin/piperaquine (Artekin®) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan childrenTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- VARIATION IN MALARIA TRANSMISSION INTENSITY IN SEVEN SITES THROUGHOUT UGANDAThe American Journal of Tropical Medicine and Hygiene, 2006
- Pharmacovigilance of antimalarial treatment in Africa: is it possible?Malaria Journal, 2006